Compare PETS & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PETS | CVM |
|---|---|---|
| Founded | 1996 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.4M | 30.1M |
| IPO Year | 2003 | 1996 |
| Metric | PETS | CVM |
|---|---|---|
| Price | $1.26 | $1.83 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $12.50 |
| AVG Volume (30 Days) | 130.4K | ★ 253.1K |
| Earning Date | 08-13-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $273,800,000.00 | $264,033.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $1.27 | $0.89 |
| 52 Week High | $4.10 | $10.24 |
| Indicator | PETS | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 14.90 | 49.64 |
| Support Level | N/A | $1.01 |
| Resistance Level | $1.91 | $4.84 |
| Average True Range (ATR) | 0.04 | 0.26 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 3.28 | 15.88 |
PetMed Express Inc is a nationwide direct-to-consumer pet pharmacy and online provider of prescription and non-prescription medications, foods, supplements, supplies, and vet services for dogs, cats, and horses. It markets and sells directly to consumers through its websites, toll-free numbers, and mobile application, offering convenience, price, speed of delivery, and customer service. It provides access to branded pharmaceuticals, generic medications, compounded prescription medications, over-the-counter health and wellness products, prescription and non-prescription food, pharmacy fulfillment, and AutoShip capabilities. Its digital platform offers pet healthcare solutions for chronic conditions, including allergies, arthritis, anxiety, kidney-related conditions, and hyperthyroidism.
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.